Bone health in postmenopausal women with early breast cancer: How protective is tamoxifen?

Cancer Treatment Reviews

Volumn 33, Issue 6, 2007, Pages 506-513

  Ding, Hongliu ^a   Field, Terry S ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Bone density; Breast cancer; Osteoporosis; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; GADOLINIUM 153; IODINE 125; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; BONE DENSITY; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY CANCER; FEMALE; FRACTURE; HIP; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; MONOTHERAPY; OSTEOLYSIS; PEER REVIEW; PHOTON ABSORPTIOMETRY; POSTMENOPAUSE; SPINE; TREATMENT OUTCOME; WOMEN'S HEALTH;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; BREAST NEOPLASMS; FEMALE; HUMANS; TAMOXIFEN;

EID: 34548381259     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.04.005     Document Type: Article

References (55)

1. American Cancer Society. Cancer facts and figures 2006. Atlanta, GA: American Cancer Society; 2006.
2. Headley J.A., Theriault R.L., LeBlanc A.D., et al. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest 16 (1998) 6-11
3. Mincey B.A., Duh M.S., Thomas S.K., et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 7 (2006) 127-132
4. Perez E.A., Josse R.G., Pritchard K.I., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24 (2006) 3629-3635
5. Wittliff J.L. Steroid-hormone receptors in breast cancer. Cancer 53 (1984) 630-643
6. Gottardis M.M., and Jordan V.C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47 (1987) 4020-4024
7. Lerner L.J., and Jordan V.C. Development of antiestrogens and their use in breast cancer: eighth cain memorial award lecture. Cancer Res 50 (1990) 4177-4189
8. Jordan V.C., Phelps E., and Lindgren J.U. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10 (1987) 31-35
9. Jordan V.C. The development of tamoxifen for breast cancer therapy: a tribute to the late arthur L. walpole. Breast Cancer Res Treat 11 (1988) 197-209
10. Turner R.T., Wakley G.K., Hannon K.S., et al. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 2 (1987) 449-456
11. Carlson R.W., Brown E., Burstein H.J., et al. NCCN task force report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw 4 (2006) S1-S26
12. Cecchini S., Ciatto S., Bonardi R., et al. Risk of endometrial cancer in breast cancer patients under long-term adjuvant treatment with tamoxifen. Tumori 84 (1998) 21-23
13. Lipton A., Harvey H.A., and Hamilton R.W. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 68 (1984) 887-889
14. Mignotte H., Sasco A.J., Lasset C., et al. Adjuvant therapy of breast cancer with tamoxifen and endometrial carcinoma. Bull Cancer 79 (1992) 969-977
15. Nevasaari K., Heikkinen M., and Taskinen P.J. Tamoxifen and thrombosis. Lancet 2 (1978) 946-947
16. Downs S.H., and Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Commun Health 52 (1998) 377-384
17. Turken S., Siris E., Seldin D., et al. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81 (1989) 1086-1088
18. Ward R.L., Morgan G., Dalley D., et al. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 22 (1993) 87-94
19. Crandall C., Petersen L., Ganz P.A., et al. Bone mineral density and adjuvant therapy in breast cancer survivors. Breast Cancer Res Treat 88 (2004) 257-261
20. Kalef-Ezra J., Glaros D., Klouvas G., et al. New evidence that tamoxifen does not induce osteoporosis: a nuclear activation analysis and absorptiometry study. Br J Radiol 65 (1992) 417-420
21. Kalef-Ezra J.A., Pavlidis N., Klouvas G., et al. Elemental composition of bone minerals in women with breast cancer treated with adjuvant tamoxifen. Breast Cancer Res Treat 37 (1996) 161-168
22. Neal A.J., Evans K., and Hoskin P.J. Does long-term administration of tamoxifen affect bone mineral density?. Eur J Cancer 29A (1993) 1971-1973
23. Ryan W.G., Wolter J., and Bagdade J.D. Apparent beneficial effects of tamoxifen on bone mineral content in patients with breast cancer: preliminary study. Osteoporos Int 2 (1991) 39-41
24. Barni S., Lissoni P., Tancini G., et al. Effects of one-year adjuvant treatment with tamoxifen on bone mineral density in postmenopausal breast cancer women. Tumori 82 (1996) 65-67
25. Fornander T., Rutqvist L.E., Wilking N., et al. Oestrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer. Eur J Cancer 29A (1993) 497-500
26. Leslie W.D., Cowden E.A., and Maclean J.P. Oestrogen and bone density: a comparison of tamoxifen and hypo-oestrogenaemia. Nucl Med Commun 16 (1995) 698-702
27. Marttunen M.B., Hietanen P., Tiitinen A., et al. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83 (1998) 1158-1162
28. Marttunen M.B., Hietanen P., Titinen A., et al. Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer. Calcified Tissue Int 65 (1999) 365-368
29. Yoneda K., Tanji Y., Ikeda N., et al. Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan. Cancer Lett 186 (2002) 223-230
30. Eastell R., Hannon R.A., Cuzick J., Dowsett M., Clack G., and Adams J.E. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230) (2006), Blackwell Science, Inc., Malden, MA
31. Tiitinen A., Nikander E., Hietanen P., et al. Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene. Maturitas 48 (2004) 321-327
32. Zidan J., Keidar Z., Basher W., et al. Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer. Med Oncol 21 (2004) 117-121
33. Kristensen B., Ejlertsen B., Dalgaard P., et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 12 (1994) 992-997
34. Resch A., Biber E., Seifert M., et al. Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer. Acta Oncol 37 (1998) 661-664
35. Love R.R., Mazess R.B., Barden H.S., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326 (1992) 852-856
36. Love R.R., Barden H.S., Mazess R.B., et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154 (1994) 2585-2588
37. Rodriguez-Rodriguez L.M., Rodriguez-Rodriguez E.M., Oramas-Rodriguez J.M., et al. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer. Breast Cancer Res Treat 93 (2005) 75-83
38. Cameron L.D., Leventhal H., Love R.R., et al. Trait anxiety and tamoxifen effects on bone mineral density and sex hormone-binding globulin. Psychosom Med 64 (2002) 612-620
39. Fornander T., Rutqvist L.E., Sjoberg H.E., et al. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 8 (1990) 1019-1024
40. Love R.R., Mazess R.B., Tormey D.C., et al. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 12 (1988) 297-302
41. Saarto T., Vehmanen L., Elomaa I., et al. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 84 (2001) 1047-1051
42. Kristensen B., Ejlertsen B., Mouridsen H.T., et al. Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 39 (1996) 321-326
43. Kanis J.A., McCloskey E.V., Powles T., et al. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79 (1999) 1179-1181
44. Powles T.J., Hickish T., Kanis J.A., et al. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14 (1996) 78-84
45. Sverrisdottir A., Fornander T., Jacobsson H., et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22 (2004) 3694-3699
46. Vehmanen L., Elomaa I., Blomqvist C., et al. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 24 (2006) 675-680
47. Douchi T., Yonehara Y., Kosha S., et al. Bone mineral density in breast cancer patients with positive estrogen receptor tumor status (2007), Maturitas
48. Chen Z., Maricic M., Bassford T.L., et al. Fracture risk among breast cancer survivors: results from the women's health initiative observational study. Arch Intern Med 165 (2005) 552-558
49. Lamont E.B., and Lauderdale D.S. Low risk of hip fracture among elderly breast cancer survivors. Ann Epidemiol 13 (2003) 698-703
50. Black D.M., Cummings S.R., Genant H.K., et al. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 7 (1992) 633-638
51. Cummings S.R., Black D.M., Nevitt M.C., et al. Bone density at various sites for prediction of hip fractures. The study of osteoporotic fractures research group. Lancet 341 (1993) 72-75
52. Sarkar S., Mitlak B.H., Wong M., et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17 (2002) 1-10
53. Sarkar S., Reginster J.Y., Crans G.G., et al. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19 (2004) 394-401
54. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90 (1998) 1371-1388
55. National Comprehensive Cancer Network. Breast cancer treatment guidelines for patients-version VIII, September 2006.